Tech Company Financing Transactions
Imvaq Therapeutics Funding Round
Imvaq Therapeutics secured a $15 million Series B funding round on 9/29/2020. Investors included Hanne Capital and private investors.
Transaction Overview
Company Name
Announced On
9/29/2020
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Hanne Capital (Lead Investor) (John Jin)
Proceeds Purpose
These funds will enable the company to catalyze the Phase 1 clinical development of its first therapeutic candidate MQ710, a novel 2nd-generation viral immunotherapy based on armed Modified Vaccinia Ankara (MVA), and to advance additional novel assets in its pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
New York, NY 10065
USA
New York, NY 10065
USA
Phone
Undisclosed
Website
Email Address
Overview
Imvaq Therapeutics is an innovative cancer immunotherapy company founded by world-leading researchers at Memorial Sloan Kettering Cancer Center. The company is developing novel viral-based, armed immune-stimulating therapies to treat a variety of metastatic solid tumors including skin cancers, sarcoma, as well as hard-to-treat tumors such as triple-negative breast cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Choi
Browse more venture capital transactions:
Prev: 9/29/2020: Exotec venture capital transaction
Next: 9/29/2020: IONpath venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs